Mounjaro will be made available on the NHS but the rollout will be phased, with only those with the highest need getting the jabs first ...
A new weight-loss jab will be rolled out on the NHS in England - but it could take 12 years for everyone to receive it, the ...
A study of two popular weight loss drugs, Zepbound and Wegovy, found that Zepbound was more effective helping people lose ...
Amid the war on obesity, a clear winner has emerged in a battle between two weight-loss injectables. Zepbound (tirzepatide), ...
Key Takeaways Patients taking Eli Lilly's Zepbound lost more weight on average than those on Novo Nordisk's Wegovy in a new ...
People taking the weight loss drug Zepbound experienced dramatically greater weight loss than competitor Wegovy in the first head-to-head trial.
More than half of Americans qualify for GLP-1 receptor agonist drugs, but many can't afford them. Experts share cheaper ...
The randomized clinical trial showed that Zepbound patients achieved 47% more relative weight loss than Wegovy patients.
Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than ...
Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical ...
Pharmaceutical giants Eli Lilly and Company & Novo Nordisk A/S face challenges in the obesity market despite promising data.
Adults who take Zepbound lose more weight than those who take competitor weight loss drug Wegovy, according to new clinical ...